Send me a link:

*Text messaging rates may apply.

 Dow Down0.72% Nasdaq Down0.50%

MiMedx Group, Inc. (MDXG)

6.30 Down 0.23(3.52%) Jul 25, 4:00PM EDT
ProfileGet Profile for:
MiMedx Group, Inc.
1775 West Oak Commons Court, NE
Marietta, GA 30062
United States - Map
Phone: 678-384-6720

Index Membership:N/A
Industry:Medical Appliances & Equipment
Full Time Employees:222

Business Summary 

MiMedx Group, Inc., together with its subsidiaries, designs, manufactures, and markets products and tissue processing services in the United States. The company’s products include patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies comprise AmnioFix and EpiFix, which are tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through the company’s donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. It processes the human amniotic membrane utilizing its proprietary PURION process to produce a safe and effective implant. The company also provides CollaFix, a medical device technology platform. It supplies amniotic tissue on OEM basis for application in the wound care, surgical, sports medicine, ophthalmic, and dental sectors of healthcare through direct sales force, independent sales representatives, and distributors, as well as through private label or OEM relationships. The company is headquartered in Marietta, Georgia.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on MiMedx Group, Inc.

Corporate Governance 
MiMedx Group, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 6; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Parker H. Petit , 75
Chairman and Chief Exec. Officer
Mr. William Charles Taylor , 45
Pres, Chief Operating Officer and Director
Mr. Michael J. Senken , 56
Chief Financial Officer, Principal Accounting Officer and VP
Ms. Roberta L. McCaw , 58
VP, Gen. Counsel and Consultant
Dr. Thomas J. Koob Ph.D., 65
Exec. VP and Chief Scientific Officer
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders